Top Page
Prenetics Group
(NASDAQ:PRE)
Prenetics Group (PRE) vs. SPDR S&P 500 ETF (SPY)
Prenetics Group Business Overview & Revenue Model
Prenetics Group Earnings Call Summary
Prenetics Group Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.04M | 92.39M | 30.62M | 21.74M | 13.16M | 12.53M |
| Gross Profit | 32.56M | 48.94M | 15.40M | 8.83M | 3.62M | 3.60M |
| EBITDA | -53.51M | -33.60M | -51.57M | -47.90M | -218.04M | -209.16M |
| Net Income | -46.55M | -58.32M | -46.30M | -62.72M | -190.45M | -174.01M |
Balance Sheet | ||||||
| Total Assets | 196.51M | 203.52M | 213.57M | 254.17M | 312.13M | 148.51M |
| Cash, Cash Equivalents and Short-Term Investments | 23.73M | 61.49M | 62.81M | 72.74M | 184.12M | 45.19M |
| Total Debt | 2.10M | 2.20M | 5.77M | 2.37M | 6.65M | 491.67M |
| Total Liabilities | 35.30M | 29.01M | 42.23M | 44.01M | 68.67M | 549.40M |
| Stockholders Equity | 161.29M | 174.60M | 170.39M | 206.36M | 237.06M | -400.81M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -22.02M | -29.94M | -14.68M | 8.17M | 2.00M |
| Operating Cash Flow | 0.00 | -21.81M | -28.87M | -13.76M | 14.51M | 13.42M |
| Investing Cash Flow | 0.00 | -35.79M | 38.54M | -82.95M | -46.14M | -22.02M |
| Financing Cash Flow | 0.00 | 37.54M | -3.34M | -4.70M | 143.32M | 29.32M |
Prenetics Group Technical Analysis
Prenetics Group Risk Analysis
Prenetics Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $322.89M | -18.61 | -19.87% | ― | 5.44% | 72.17% | |
56 Neutral | $337.58M | -4.69 | -23.93% | ― | 159.45% | 8.59% | |
54 Neutral | $343.45M | -2.34 | -113.23% | ― | -41.87% | -165.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $182.15M | -5.68 | -720.01% | ― | 21.68% | 58.30% | |
44 Neutral | $94.51M | -1.62 | -239.53% | ― | 78.62% | 32.39% | |
44 Neutral | $74.33M | -3.53 | -122.81% | ― | 14.08% | 1.34% |
Prenetics Group Corporate Events
Prenetics Global Limited, a consumer health sciences company and parent of the IM8 premium health and longevity brand, reported that 2025 was a transformational year marked by record growth and a strategic refocus on IM8. The company divested non-core units including ACT Genomics, its Europa distribution business and its stake in Insighta, resulting in about $171 million of adjusted liquidity and a simplified operating structure as of mid-February 2026.
For the year ended December 31, 2025, Prenetics’ revenue surged about 480% year over year to $92.4 million, with fourth-quarter revenue reaching $36.6 million on strong IM8 momentum. IM8 generated $60.1 million of 2025 revenue, hit $10 million in monthly sales in December and achieved an annualized recurring revenue run-rate of roughly $120 million just 12 months after launch.
The IM8 business showed robust unit economics in 2025, including a blended average order value of about $110, a roughly 3.4‑month payback period and a projected 24‑month lifetime value-to-customer acquisition cost ratio of about 3x. By the end of the fourth quarter, IM8’s quarterly revenue rose 59% from the prior quarter, while customer orders and servings delivered grew more than 30%, underscoring strong product-market fit and recurring demand.
Geographically, IM8’s $60.1 million in 2025 revenue was diversified, with the United States accounting for $23.8 million, followed by Canada, the United Kingdom, Australia and Singapore, and more than 60% of revenue coming from outside the U.S. The company reported that IM8 shipped to over 30 countries during the year, establishing a global footprint that supports its expansion plans in 2026.
In late 2025 and early 2026, Prenetics shifted new IM8 customers from monthly to quarterly subscription plans to boost upfront cash flow and improve logistics efficiency. This move drove a step-change in blended average order value from about $110 for full-year 2025 to $133 in the fourth quarter and roughly $233 for new customers in January and February 2026, albeit with a deliberate increase in customer acquisition costs to secure higher-value, longer-duration subscribers.
To support brand positioning, Prenetics deepened IM8’s ties to elite sports by adding world No. 1 tennis player Aryna Sabalenka as a global ambassador and shareholder in June 2025 and Formula 1 driver Ollie Bearman in February 2026. These partnerships, alongside co-founder David Beckham, are intended to reinforce IM8’s image as a premium performance and recovery brand and to broaden its reach among health-focused consumers and athletes worldwide.
The most recent analyst rating on (PRE) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On February 17, 2026, Prenetics Global Limited announced board changes tied to its strategic pivot toward scaling IM8 as a global health and longevity brand. Director Kong Yiu (Andy) Cheung resigned effective February 16, 2026, a move the company said was aligned with its sharpened focus on IM8 and followed its December 4, 2025 decision to halt any future purchases of Bitcoin or other cryptocurrencies.
The company simultaneously appointed longevity expert and health-tech entrepreneur Dr. Darshan Shah as an independent director, effective February 16, 2026, adding him to its audit, compensation, and nominating committees. Shah’s background as a Mayo Clinic-trained surgeon, founder and CEO of Next Health, and nationally recognized product formulator is expected to reinforce Prenetics’ clinical rigor and commercial capabilities as it pursues data-driven clinical trials and global expansion of IM8’s science-backed product ecosystem.
Management framed these moves as strengthening board-level scientific and commercial oversight at a key inflection point for IM8’s growth. For investors and other stakeholders, the exit from crypto exposure and the addition of a high-profile longevity specialist underscore Prenetics’ commitment to its core consumer health strategy and to building long-term value around the IM8 platform.
The most recent analyst rating on (PRE) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On February 17, 2026, Prenetics Global Limited announced it had completed the sale of its 35% equity stake in cancer-screening venture Insighta to Tencent for $70 million in cash, marking the final step in a wider strategic overhaul. The deal lifts Prenetics’ total adjusted liquidity to $171.1 million as of February 15, 2026, including $99.3 million in cash and cash equivalents and $35.2 million in Bitcoin, while the company continues to operate with no debt.
Management framed the divestment as the most significant milestone in its transformation to streamline operations and concentrate resources on scaling IM8, its fast-growing global consumer health brand. The strengthened balance sheet, supported by non-dilutive capital from the Tencent transaction and prior asset sales, is expected to give Prenetics greater financial flexibility to fund IM8’s international expansion, product innovation and clinical trials, with further details to be discussed alongside its fourth-quarter and full-year 2025 results on February 18, 2026.
The most recent analyst rating on (PRE) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On January 1, 2026, Prenetics Global Limited completed the sale of its third-party logistics distribution business operated by subsidiary Europa Sports Partners in an all-stock transaction valued at up to $13 million, as disclosed in a January 6, 2026 filing. The divestiture, which follows the $72 million sale of ACT Genomics in October 2025, is part of an ongoing portfolio optimization that concentrates capital and management attention on IM8, the company’s fastest-growing, highest-margin business line, with management highlighting an expected improvement in operating margins from the second quarter of 2026 as Prenetics exits roughly $6 million in annual operating losses tied to the non-core Europa unit. The transaction leaves fiscal 2025 results unchanged because the sale closed at the start of 2026, while Prenetics maintains a strong liquidity position of more than $70 million in cash and equivalents plus Bitcoin holdings and continues a strategic review of additional non-core assets, including its 35% stake in Insighta, with the stated objective of simplifying its structure and maximizing shareholder returns as IM8 scales globally.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On January 5, 2026, Prenetics Global Limited reported that participation in its voluntary warrant exchange program tied to its October 2025 financing round had reached approximately 86.7%, with exchange agreements now covering about 4.72 million of the 5.45 million Class A and Class B warrants originally issued. Those warrants are expected to be exchanged into roughly 2.36 million Class C warrants, cutting the total outstanding warrant count to about 3.08 million—around a 43.3% reduction—and lowering potential dilution on full exercise to about 18.3% of outstanding shares, down from roughly 32.3%. Management indicated that the higher take‑up since its December 23, 2025 update should simplify the company’s capital structure and improve the investability of its ordinary shares; the new Class C warrants carry a lower exercise price, shorter term and a forced-redemption feature, and the exchange was conducted on identical, voluntary terms for all eligible holders.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On December 30, 2025, Prenetics Global Limited announced a major capital allocation shift, confirming that it stopped its daily Bitcoin purchases on December 4 and will no longer deploy capital into additional cryptocurrency acquisitions. The company will retain its current holding of 510 Bitcoin as a treasury reserve asset while redirecting all new and existing capital exclusively toward scaling IM8, its high-growth consumer health brand, which has already exceeded $100 million in annualized recurring revenue and is projected to generate $180–$200 million in revenue in fiscal 2026. Backed by a debt-free balance sheet with more than $70 million in cash and cash equivalents, the move consolidates Prenetics’ strategic focus around IM8’s rapid global expansion, product innovation, and brand-building efforts, aiming to enhance long-term shareholder value and sharpen its positioning in the competitive wellness and longevity sector.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On December 23, 2025, Prenetics Global Limited announced that it had entered into warrant exchange agreements with holders representing about 83.4% of its outstanding Class A and Class B warrants issued in an October 2025 financing. Under the voluntary program, investors exchanged one Class A and one Class B warrant—previously exercisable at $24.12 and $32.16, respectively, with five-year terms—for a single new Class C warrant exercisable at $18.00 per share for two years once a resale registration statement on Form F-3 becomes effective, and subject to a forced-redemption feature if the stock trades at or above $21.60 for ten consecutive trading days. The transaction, supported by several of Prenetics’ largest institutional shareholders, is expected to swap roughly 4.54 million legacy warrants for about 2.27 million Class C warrants, cutting the total warrant overhang to around 3.18 million instruments—about a 42% reduction from the October issuance, and up to 50% if all holders ultimately participate. Management says the move simplifies the capital structure, materially improves the company’s long-term dilution profile, and enhances the investability of its ordinary shares, while emphasizing that the exchange is not tied to any new financing and that Prenetics has no near-term plans for additional equity or equity-linked capital raising.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Prenetics Global Limited, a company involved in the healthcare industry, has announced that it will hold its 2025 annual general meeting of shareholders on December 19, 2025. This meeting will provide an open forum for shareholders to discuss company affairs with management and transact any other business brought before the meeting. The record date for determining shareholders entitled to notice of the meeting is December 11, 2025. This announcement is significant as it allows shareholders to engage directly with the company’s management, potentially impacting future company strategies and decisions.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
On November 24, 2025, Prenetics Global Limited announced that its executive leadership team purchased approximately $1.45 million worth of the company’s common stock in open market transactions. This move, involving key figures such as CEO Danny Yeung and CFO Stephen Lo, underscores the executives’ confidence in Prenetics’ long-term vision and growth potential. The purchases reflect a strong alignment with shareholders and a belief in the company’s future, particularly as IM8 continues to expand rapidly and the company’s Bitcoin-treasury strategy supports financial resilience.
The most recent analyst rating on (PRE) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.